Back to results
US 2019/0160170 A1Published application
Antibodies binding axl
AssigneeGenmab A/S
InventorsEsther Breij, David Satijn, Edward Norbert Van Den Brink, Dennis Verzijl, Rob N. De Jong, Paul Parren, Riemke Van Dijkhuizen Radersma
Life of this patent
Estimating the term…
Abstract
The present invention relates to anti-AXL antibodies, immunoconjugates, compositions and method of treatment of cancer with such anti-AXL antibodies, immunoconjugates, or compositions.
Claims30
1-62. (canceled)
An immunoconjugate comprising (a) an antibody which binds to AXL (SEQ ID NO:
- 130) and comprises a heavy chain variable (VH) region and a light chain variable (VL) region, wherein the VH region comprises the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NOs:
- 36, 37, and 38, respectively, and the VL region comprises the CDR1, CDR2, and CDR3 sequences set forth in SEQ ID NO:
- 39, the amino acid sequence GAS, and SEQ ID NO:
- 40, respectively, (b) a mc-vc-PAB linker, and (c) MMAE.
1 more element
An immunoconjugate comprising (a) an antibody which binds to AXL (SEQ ID NO:
- 130) and comprises a heavy chain variable (VH) region and a light chain variable (VL) region, wherein the VH region comprises the amino acid sequence of SEQ ID NO:
- 1 and the VL region comprises the amino acid sequence of SEQ ID NO:
- 2, (b) a mc-vc-PAB linker, and (c) MMAE.
Dependencies are inferred from the claim text.